Overview

A Phase 3 Randomized, Double-Blind Placebo Controlled, Multi-regional Trial to Evaluate the Efficacy and Safety of GT0918 for the Treatment of Mild to Moderate COVID-19 Male Patients

Status:
Recruiting
Trial end date:
2022-05-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the efficacy and safety of Proxalutamide (GT0918) in male outpatients with mild to moderate COVID-19 disease
Phase:
Phase 3
Details
Lead Sponsor:
Suzhou Kintor Pharmaceutical Inc,
Collaborators:
Syneos Health
Thermo Fisher Scientific